Active substancePhenylephrinePhenylephrine Similar drugsTo uncover Bebifrin drops nazal. GROTEKS, LLC Russia Visofrin drops d / eye LEKKO, ZAO Russia Irifrin® drops d / eye Sentiss Pharma Pvt.Ltd. India Irifrin® BK drops d / eye Sentiss Pharma Pvt. Ltd. India Mesatone solution for injections EXPERIMENTAL FACTORY ГНЦЛС, ООО Ukraine Mesatone solution for injections DALHIMFARM, OJSC Russia Nazol® Baby drops nazal. BAYER, AO Russia Nazol® Kids spray d / children nazal. BAYER, AO Russia Neosinephrine-PIC® drops d / eye Ursafarm Artsnaymittel GmbH Germany Relief® ointment rect. externally BAYER, AO Russia Stelfryn solution for injections GROTEKS, LLC Russia Phenylephrine-SOLOfarm drops d / eye GROTEKS, LLC Russia Dosage form: & nbspnasal drops Composition:100 ml contains: active substance: phenylephrine hydrochloride 0.125 g; Excipients: benzalkonium chloride 0.018 g, glycerol 5 g, macrogol 1500 1.5 g, sodium hydrogen phosphate dihydrate 0.226 g, potassium dihydrogen phosphate 0.101 g, disodium edetate dihydrate 0.02 g, purified water 94.76 g Description:Transparent solution from colorless to light yellow color, odorless. Pharmacotherapeutic group:Alpha-adrenomimetic ATX: & nbspS.01.F.B.01 Ibopamine Pharmacodynamics:Phenylephrine hydrochloride is an alpha 1-adrenergic receptor agonist (sympathomimetic),which has vasoconstrictive effect due to stimulation of alpha-1 receptors in the mucous membranes of the nose, reduces swelling of mucous membranes and flushing of tissues, stagnation in the mucous membrane of the nose, and improves the patency of the nasal airways. Pharmacokinetics:With topical application, systemic absorption is low. Indications:Symptomatic treatment: to facilitate breathing through the nose for colds, flu, hay fever or other allergic diseases of the upper respiratory tract, accompanied by acute rhinitis or sinusitis. Contraindications:Increased individual sensitivity to the ingredients of the drug; diseases of the cardiovascular system (including coronarosclerosis, stenocardia), hypertensive crisis, thyrotoxicosis, diabetes mellitus, simultaneous administration of MAO inhibitors (and also 2 weeks after their cancellation). Carefully:Children under 6 years. Pregnancy and lactation:Sufficient experience in the use of the drug during pregnancy is not present. Possible application for the treatment of pregnant and lactating mothers as prescribed by the attending physician,if the potential benefit to the mother exceeds the possible risk to the fetus and the child. Dosing and Administration:Intranasally. For children aged 0 to 1 year single dose - 1 drop not more often than every 6 hours. For children aged 1 to 6 years single dose is 1-2 drops. For children over 6 years of age and adults single dose is 3-4 drops. After use, wipe the pipette dry. Duration of treatment - no more than 3 days. Side effects:Local Reactions: sometimes burning, tingling or tingling in the nose. System Effects: headache, dizziness, palpitations, arrhythmia, increased blood pressure, sweating, paleness, tremor, sleep disturbance. Overdose:Data on drug overdose are absent. Potentially possible symptoms (with systemic absorption): ventricular extrasystole, short paroxysms of ventricular tachycardia, sensation of heaviness in the head and extremities, excessive increase in arterial pressure, agitation. Treatment: intravenous administration of short-acting alpha-blockers (phentolamine) and beta-adrenoblockers (in case of rhythm disturbances). Interaction:Inhibitors of monoamine oxidase (procarbazine, selegin), tricyclic antidepressants, maprotiline, guanedrel, guanethidine increase the pressor effect and arrhythmogenicity of phenylephrine (with systemic absorption). Thyroid hormones increase (coupled with systemic absorption of phenylephrine) the associated risk of coronary insufficiency (especially in coronary atherosclerosis). Special instructions:Children from 0 to 1 year old should be used strictly according to the doctor's prescription and not more often than every 6 hours. In children, the systemic absorption of phenylephrine and the associated risk of side effects are higher than in adults. Do not assign phenylephrine patients within 2 weeks after the abolition of monoamine oxidase inhibitors, as they can increase the severity of adrenergic effects of sympathomimetics and increase the risk of side effects from the cardiovascular system. Form release / dosage:Nasal drops, 0.125%. Packaging:By 5, 10, 15 and 30 ml into a bottle of high density polyethylene with a screw cap made of polypropylene. A pipette made of polypropylene with a rubber cap is mounted in the lid. A label is attached to the bottle.The bottle, along with instructions for medical use, is placed in a cardboard box. Storage conditions:At a temperature of no higher than 30 ° C. Keep out of the reach of children. Shelf life:2 years. Do not use after expiry date. Terms of leave from pharmacies:Without recipe Registration number:П N016016 / 01 Date of registration:18.09.2009 / 18.05.2016 Expiration Date:Unlimited The owner of the registration certificate:BAYER, AO BAYER, AO Russia Manufacturer: & nbspINSTITUTO de ANGELI, S.r.L. Italy Representation: & nbspBAYER, AOBAYER, AO Information update date: & nbsp29.05.2018 Illustrated instructions × Illustrated instructions Instructions